For relevance BD1 has 5 quarters of cash left we all know how fast medi companies burn cash on R and D and their ROE (return on equity) is almost negative permanently (9/10 years) ditto their earnings; ZNO does not need to answer the question of cash quarters because it is cash flow positive every quarter. Further their ROE fy '20 was near +80%. I'll stay the course with the profitable one thanks.
